<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="316d0e19-cb92-1e55-e063-6294a90ab687"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use EDARAVONE INJECTION safely and effectively. See full prescribing information for EDARAVONE INJECTION.
  <br/>
         <br/>
EDARAVONE injection, for intravenous use
  <br/>
         <br/>
Initial U.S. Approval: 2017
 </content>
   </title>
   <effectiveTime value="20250328"/>
   <setId root="a8245a98-2ccb-4062-b865-3aa348351b48"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="117380305"/>
            <name>XGen Pharmaceuticals DJB, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="117380305"/>
                  <name>XGen Pharmaceuticals DJB, Inc.</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="33627146-5772-ed82-e063-6294a90ad1f3"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250328"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="39822-4500" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>edaravone</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>edaravone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="TZX5469Z6I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BISULFITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="ZT934N0X4W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CYSTEINE HYDROCHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="E4GA8884NN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHOSPHORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="30"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="S798V6YJRP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDARAVONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="S798V6YJRP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EDARAVONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="39822-4500-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="39822-4500-2" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20241202"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA217565" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20241202"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="39822-4510" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>edaravone</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>edaravone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="40"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="TZX5469Z6I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BISULFITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="ZT934N0X4W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CYSTEINE HYDROCHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="E4GA8884NN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHOSPHORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="60"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="S798V6YJRP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDARAVONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="S798V6YJRP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EDARAVONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="39822-4510-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20241202"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA217565" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20241202"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_6c80e3f2-9030-4370-b5e4-2b3ac6b307a2">
               <id root="254ffb44-3afc-4421-e063-6394a90add5c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1 INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS).</paragraph>
               </text>
               <effectiveTime value="20240930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS). (
     <linkHtml href="#LINK_6c80e3f2-9030-4370-b5e4-2b3ac6b307a2">1</linkHtml>)
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_2d329ef7-d842-4b04-8995-95b13b722f5c">
               <id root="254fd9bf-a305-753e-e063-6394a90acf44"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2 DOSAGE AND ADMINISTRATION</content>
               </title>
               <text/>
               <effectiveTime value="20240930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Edaravone injection: The recommended dosage is 60 mg administered as an intravenous infusion over 60 minutes (
     <linkHtml href="#LINK_de43b3ae-2bdc-42b1-99e7-4e9e64255fb3">2.1</linkHtml>)
    </item>
                           <item>Initial treatment cycle: daily dosing for 14 days followed by a 14- day drug-free period (
     <linkHtml href="#LINK_de43b3ae-2bdc-42b1-99e7-4e9e64255fb3">2.1</linkHtml>)
    </item>
                           <item>Subsequent treatment cycles: daily dosing for 10 days out of 14- day periods, followed by 14-day drug-free periods (
     <linkHtml href="#LINK_de43b3ae-2bdc-42b1-99e7-4e9e64255fb3">2.1</linkHtml>)
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_de43b3ae-2bdc-42b1-99e7-4e9e64255fb3">
                     <id root="254ffb44-3aff-4421-e063-6394a90add5c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 Dosage Information</content>
                     </title>
                     <text>
                        <paragraph>The recommended dosage of edaravone injection is as follows:</paragraph>
                        <list listType="unordered">
                           <item>an intravenous infusion of 60 mg administered over a 60-minute period.</item>
                        </list>
                        <paragraph>Administer edaravone injection according to the following schedule:</paragraph>
                        <list listType="unordered">
                           <item>An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug-free period</item>
                           <item>Subsequent treatment cycles with daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods</item>
                        </list>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8f6f9eda-b9dd-448a-a787-e9318eccdc35">
                     <id root="254ffb44-3b02-4421-e063-6394a90add5c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 Preparation and Administration Information for Edaravone Injection</content>
                     </title>
                     <text>
                        <paragraph>Edaravone injection is for intravenous infusion only.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Preparation</content>
                        </paragraph>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
                        <paragraph>Vial may be inverted for use with a medical infusion set. Prepare the dose for administration by inserting a vented intravenous set through the septum of the 100 mL vial. Examine the container contents before dose preparation or administering. DO NOT USE if particulate matter or discoloration is observed, or if the flip off seal is not intact.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Administration</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">30 mg/100 mL single-dose vials:</content>
                           </content>Administer each 60 mg dose of edaravone injection as two consecutive 30 mg intravenous infusion single-dose vials over a total of 60 minutes (infusion rate approximately 1 mg per minute [3.33 mL per minute]).
 </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">60 mg/100 mL single-dose vials:</content>
                           </content>Administer a 60 mg dose of edaravone injection as an intravenous infusion single-dose vial over a total of 60 minutes (infusion rate approximately 1 mg per minute [1.67 mL per minute]).
 </paragraph>
                        <paragraph>Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction 
  <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (
   <linkHtml href="#LINK_61a646af-fb4f-47da-8a04-d800e6075f02">5.1</linkHtml>, 
   <linkHtml href="#LINK_35f3097b-ee84-4bc0-8ac3-db6c06f198ca">5.2</linkHtml>)]
  </content>.
 </paragraph>
                        <paragraph>Other medications should not be injected into the single-dose vial or mixed with edaravone injection.</paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2833ab7c-8ab1-43dc-8a5c-fdfae00ffb13">
                     <id root="254fdf80-d3f9-c87b-e063-6394a90a66f4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.4 Switching from Edaravone Injection to RADICAVA ORS®</content>
                     </title>
                     <text>
                        <paragraph>Patients treated with 60 mg of edaravone intravenous infusion may be switched to 105 mg (5 mL) RADICAVA ORS® using the same dosing frequency. </paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_806d0c6f-0ec3-462c-9c4e-cffda61e6b5e">
               <id root="25506a1a-a6f6-3852-e063-6394a90acd7a"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3 DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>Edaravone injection is supplied for intravenous infusion in a single-dose USP Type 1 Glass Vial containing 
  <content styleCode="bold">30 mg </content>or 
  <content styleCode="bold">60 mg</content>of edaravone in 100 mL of clear, colorless aqueous solution.
 </paragraph>
               </text>
               <effectiveTime value="20240930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Injection: 30 mg/100 mL in a single-dose USP Type 1 Glass Vial (
     <linkHtml href="#LINK_806d0c6f-0ec3-462c-9c4e-cffda61e6b5e">3</linkHtml>)
    </item>
                           <item>Injection: 60 mg/100 mL in a single-dose USP Type 1 Glass Vial (
     <linkHtml href="#LINK_806d0c6f-0ec3-462c-9c4e-cffda61e6b5e">3</linkHtml>)
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_9f1dbf07-9b0a-4118-b8de-84f4da24688f">
               <id root="25505c67-0b5f-4fda-e063-6394a90aa421"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4 CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>Edaravone injection is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in this product. Hypersensitivity reactions and anaphylactic reactions have occurred 
  <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (
   <linkHtml href="#LINK_61a646af-fb4f-47da-8a04-d800e6075f02">5.1</linkHtml>, 
   <linkHtml href="#LINK_35f3097b-ee84-4bc0-8ac3-db6c06f198ca">5.2</linkHtml>)]
  </content>.
 </paragraph>
               </text>
               <effectiveTime value="20240930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in edaravone injection (
    <linkHtml href="#LINK_9f1dbf07-9b0a-4118-b8de-84f4da24688f">4</linkHtml>)
   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_033366bb-fec1-4829-996b-088357ab1f06">
               <id root="254fcafb-a0c3-1d9d-e063-6294a90a84c6"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5 WARNINGS AND PRECAUTIONS</content>
               </title>
               <text/>
               <effectiveTime value="20240930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Hypersensitivity Reactions: Advise patients to seek immediate medical care (
     <linkHtml href="#LINK_61a646af-fb4f-47da-8a04-d800e6075f02">5.1</linkHtml>)
    </item>
                           <item>Sulfite Allergic Reactions: Edaravone injection contains sodium bisulfite, which may cause allergic type reactions, including anaphylactic symptoms and asthmatic episodes in susceptible people (
     <linkHtml href="#LINK_35f3097b-ee84-4bc0-8ac3-db6c06f198ca">5.2</linkHtml>)
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_61a646af-fb4f-47da-8a04-d800e6075f02">
                     <id root="255094c0-9253-bdf6-e063-6394a90aa8f1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1 Hypersensitivity Reactions</content>
                     </title>
                     <text>
                        <paragraph>Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported in spontaneous postmarketing reports with edaravone injection.</paragraph>
                        <paragraph>Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue edaravone injection, treat per standard of care, and monitor until the condition resolves 
  <content styleCode="italics">[see 
   <linkHtml href="#LINK_9f1dbf07-9b0a-4118-b8de-84f4da24688f">CONTRAINDICATIONS (4)</linkHtml>]
  </content>.
 </paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_35f3097b-ee84-4bc0-8ac3-db6c06f198ca">
                     <id root="25508599-a934-6682-e063-6394a90a5ee5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2 Sulfite Allergic Reactions</content>
                     </title>
                     <text>
                        <paragraph>Edaravone injection contains sodium bisulfite, a sulfite that may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown. Sulfite sensitivity occurs more frequently in asthmatic than non-asthmatic people.</paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_385d18ac-23f4-4b06-9138-26345a392c2c">
               <id root="2550a64f-9a8e-6df9-e063-6294a90a2802"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6 ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following serious adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Hypersensitivity Reactions 
   <content styleCode="italics">[see 
    <linkHtml href="#LINK_61a646af-fb4f-47da-8a04-d800e6075f02">WARNINGS AND PRECAUTIONS (5.1)</linkHtml>]
   </content>
                     </item>
                     <item>Sulfite Allergic Reactions 
   <content styleCode="italics">[see 
    <linkHtml href="#LINK_35f3097b-ee84-4bc0-8ac3-db6c06f198ca">WARNINGS AND PRECAUTIONS (5.2)</linkHtml>]
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (at least 10% of patients treated with edaravone injection and greater than placebo) are contusion, gait disturbance, and headache (
    <linkHtml href="#Lbd162216-890b-4184-a59c-0bdb0f856e13">6.1</linkHtml>)
   </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact XGen Pharmaceuticals DJB, Inc. at 1-866-390-4411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Lbd162216-890b-4184-a59c-0bdb0f856e13">
                     <id root="255090ba-e417-be1a-e063-6394a90af34b"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.1 Clinical Trials Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In randomized, placebo-controlled trials, 184 patients with ALS were administered edaravone injection 60 mg in treatment cycles for 6 months. The population consisted of Japanese patients who had a median age of 60 years (range 29-75) and were 59% male. Most (93%) of these patients were living independently at the time of screening.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Most Common Adverse Reactions Observed During Clinical Studies</content>
                        </paragraph>
                        <paragraph>Table 2 lists the adverse reactions that occurred in ≥2% of patients in the edaravone injection-treated group and that occurred at least 2% more frequently than in the placebo-treated group in randomized placebo-controlled ALS trials. The most common adverse reactions that occurred in ≥10% of edaravone injection-treated patients were contusion, gait disturbance, and headache.</paragraph>
                        <table width="60%">
                           <caption>Table 2: Adverse Reactions from Pooled Placebo-Controlled Trials
   <sup>a </sup>that Occurred in ≥2% of Edaravone Injection-Treated Patients and ≥2% More Frequently than in Placebo Patients
  </caption>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule">
                                    <paragraph>
                                       <content styleCode="bold">Edaravone Injection </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=184)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=184)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule">Contusion</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 15</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule">Gait disturbance</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 13</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule">Headache</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 10</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule">Dermatitis</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 8</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule">Eczema</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 7</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule">Respiratory failure, respiratory disorder, hypoxia</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 6</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule">Glycosuria</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 4</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule">Tinea infection</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 4</td>
                                 <td styleCode="Lrule Rrule Toprule Botrule"> 2</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup>Pooled placebo-controlled studies include two additional studies with 231 additional patients, all using the same treatment regimen 
  <content styleCode="italics">[see 
   <linkHtml href="#LINK_5636b5b7-b3cb-4097-901f-286147605c85">CLINICAL STUDIES (14)</linkHtml>]
  </content>.
 </paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
               <component>
                  <section ID="L01ddfe01-946b-4330-a019-cfcc42b4acc1">
                     <id root="2550c1a3-fc81-4bb0-e063-6294a90a3e97"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.2 Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of edaravone injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and subcutaneous tissue disorders: Hypersensitivity reactions and anaphylaxis [see WARNINGS AND PRECAUTIONS (
   <linkHtml href="#LINK_61a646af-fb4f-47da-8a04-d800e6075f02">5.1</linkHtml>, 
   <linkHtml href="#LINK_35f3097b-ee84-4bc0-8ac3-db6c06f198ca">5.2</linkHtml>)].
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_114be9b1-d675-4681-89fe-ab669a542b31">
               <id root="254ff01e-6c3c-2624-e063-6394a90a2ee3"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20240930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Pregnancy: Based on animal data, may cause fetal harm. (
    <linkHtml href="#LINK_f3b5e246-a1b2-40bc-b38a-b6d17e6c1b81">8.1</linkHtml>)
   </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">See 
     <linkHtml href="#LINK_1c7becee-f43f-423e-91fa-d91ef76bd278">17</linkHtml> for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
    </content>
                        </paragraph>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_f3b5e246-a1b2-40bc-b38a-b6d17e6c1b81">
                     <id root="2550e955-1f48-8dba-e063-6394a90a3e72"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1 Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no adequate data on the developmental risk associated with the use of edaravone injection in pregnant women. In animal studies, administration of edaravone to pregnant rats and rabbits resulted in adverse developmental effects (increased mortality, decreased growth, delayed sexual development, and altered behavior) at clinically relevant doses. Most of these effects occurred at doses that were also associated with maternal toxicity (
  <content styleCode="italics">see ANIMAL DATA</content>).
 </paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk for major birth defects and miscarriage in patients with ALS is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>In rats, intravenous administration of edaravone (0, 3, 30, or 300 mg/kg/day) throughout the period of organogenesis resulted in reduced fetal weight at all doses. In dams allowed to deliver naturally, offspring weight was reduced at the highest dose tested. Maternal toxicity was also observed at the highest dose tested. There were no adverse effects on reproductive function in the offspring. A no-effect dose for embryofetal developmental toxicity was not identified; the low dose is less than the recommended human dose of 60 mg for edaravone injection on a body surface area (mg/m
  <sup>2</sup>) basis.
 </paragraph>
                        <paragraph>In rabbits, intravenous administration of edaravone (0, 3, 20, or 100 mg/kg/day) throughout the period of organogenesis resulted in embryofetal death at the highest dose tested, which was associated with maternal toxicity. The higher no-effect dose for embryofetal developmental toxicity is approximately 6 times the recommended human dose (RHD) for edaravone injection on a body surface area (mg/m
  <sup>2</sup>) basis.
 </paragraph>
                        <paragraph>The effects on offspring of edaravone (0, 3, 20, or 200 mg/kg/day), administered by intravenous injection to rats from GD 17 throughout lactation, were assessed in two studies. In the first study, offspring mortality was observed at the high dose and increased activity was observed at the mid and high doses. In the second study, there was an increase in stillbirths, offspring mortality, and delayed physical development (vaginal opening) at the highest dose tested. Reproduction function in offspring was not affected in either study. Maternal toxicity was evident in both studies at all but the lowest dose tested. The no-effect dose for developmental toxicity (3 mg/kg/day) is less than the RHD on a mg/m
  <sup>2</sup> basis.
 </paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
               <component>
                  <section ID="Lc836ab95-0e14-455d-b675-89c0733a066d">
                     <id root="2550e46a-4f94-420f-e063-6394a90a1e95"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.2 Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of edaravone in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Edaravone and its metabolites are excreted in the milk of lactating rats. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for edaravone injection and any potential adverse effects on the breastfed infant from edaravone injection or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
               <component>
                  <section ID="La2fe2f37-89f6-447d-8dcf-257f1a134d38">
                     <id root="2550cf01-136e-fdcf-e063-6294a90ab327"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4 Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Safety and effectiveness of edaravone injection in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_bd1ec273-b955-44d4-9dd1-16e43c246025">
                     <id root="2550f32c-fabf-6e13-e063-6394a90af5ce"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5 Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>Of the 184 patients with ALS who received edaravone injection in 3 placebo-controlled clinical trials, a total of 53 patients were 65 years of age and older, including 2 patients 75 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b9a6e3fe-1d09-4536-a78f-6bda7fee622d">
               <id root="2550f829-2620-960d-e063-6394a90a9cc3"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11 DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>The active ingredient in edaravone injection is edaravone, which is a member of the substituted 2-pyrazolin-5-one class. The chemical name of edaravone is [3-methyl-1-phenyl-2-pyrazolin-5-one]. The molecular formula is C
  <sub>10</sub>H
  <sub>10</sub>N
  <sub>2</sub>O and the molecular weight is 174.20.
 </paragraph>
                  <paragraph>The chemical structure is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Edaravone is a white crystalline powder with a melting point of 129.7°C. It is freely soluble in acetic acid, methanol, or ethanol and slightly soluble in water or diethyl ether.</paragraph>
                  <paragraph>Edaravone injection is a clear, colorless liquid provided as a sterile solution.</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">30 mg/100 mL single-dose vials:</content>
                     </content>Edaravone injection is supplied for intravenous infusion in a USP Type 1 Glass Vial containing 30 mg edaravone in 100 mL isotonic, sterile, aqueous solution. Individual vial will be placed in a carton (secondary packaging). Each single-dose vial contains the following inactive ingredients: L-cysteine hydrochloride hydrate (10 mg), sodium bisulfite (20 mg). Sodium chloride is added for isotonicity and phosphoric acid and sodium hydroxide are added to adjust to pH 4.
 </paragraph>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">
                        <content styleCode="italics">60 mg/100 mL single-dose vials:</content>
                     </content>Edaravone injection is supplied for intravenous infusion in a USP Type 1 Glass Vial containing 60 mg edaravone in 100 mL isotonic, sterile, aqueous solution. Individual vial will be placed in a carton (secondary packaging). Each single-dose vial contains the following inactive ingredients: L-cysteine hydrochloride hydrate (20 mg), sodium bisulfite (40 mg). Sodium chloride is added for isotonicity and phosphoric acid and sodium hydroxide are added to adjust to pH 4.
 </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20240930"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>edrv-structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="edrv-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_375ee8a5-bda4-4f6b-aaf9-792d3f6d3302">
               <id root="2553b36a-9626-38cd-e063-6394a90a9047"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12 CLINICAL PHARMACOLOGY</content>
               </title>
               <text/>
               <effectiveTime value="20240930"/>
               <component>
                  <section ID="LINK_8bfa8799-3161-4cf7-bfab-648bbff5a93b">
                     <id root="2553b847-e003-ba18-e063-6394a90ae35c"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1 Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>The mechanism by which edaravone injection exerts its therapeutic effect in patients with ALS is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_bbcd236e-da7e-433b-9b18-62c6d0a0cba6">
                     <id root="2553a4b1-62f8-5e08-e063-6294a90abe5c"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2 Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At exposures at least 5 times higher than that of the recommended doses of edaravone injection, edaravone does not prolong the QT interval to any clinically relevant extent.</paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7bfe1ea0-ad19-4927-ab5c-4b9176bd76c9">
                     <id root="2553d49b-adbb-cb78-e063-6394a90a6d5f"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3 Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>Edaravone injection is administered by IV infusion. The maximum plasma concentration (C
  <sub>max</sub>) of edaravone was reached by the end of infusion. There was a trend of more than dose-proportional increase in area under the concentration-time curve (AUC) and C
  <sub>max </sub>of edaravone. With multiple-dose administration, edaravone does not accumulate in plasma.
 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Edaravone is bound to human serum proteins (92%), mainly to albumin, with no concentration dependence in the range of 0.1 to 50 micromol/L. Edaravone has a mean volume of distribution after intravenous administration of 63.1 L.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The mean terminal elimination half-life of edaravone is approximately 4.5 to 9 hours. The half-lives of its metabolites are 3 to 6 hours. Following intravenous administration, the total clearance of edaravone is estimated to be 35.9 L/h.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Edaravone is metabolized to a sulfate conjugate and a glucuronide conjugate, which are not pharmacologically active. The glucuronide conjugation of edaravone involves multiple uridine diphosphate glucuronosyltransferase (UGT) isoforms (UGT1A1, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B17). In human plasma, edaravone is mainly detected as the sulfate conjugate, which is presumed to be formed by sulfotransferases.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>In Japanese and Caucasian healthy volunteer studies, edaravone was excreted mainly in the urine as its glucuronide conjugate (60-80% of the dose up to 48 hours). Approximately 6-8% of the dose was recovered in the urine as the sulfate conjugate, and &lt; 1% of the dose was recovered in the urine as the unchanged drug. 
  <content styleCode="italics">In vitro</content> studies suggest that the sulfate conjugate of edaravone is hydrolyzed back to edaravone, which is then converted to the glucuronide conjugate in the kidney before excretion into the urine.
 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Geriatric Patients</content>
                        </paragraph>
                        <paragraph>No age effect on edaravone pharmacokinetics has been found [see 
  <content styleCode="italics">
                              <linkHtml href="#LINK_bd1ec273-b955-44d4-9dd1-16e43c246025">USE IN SPECIFIC POPULATIONS (8.5)</linkHtml>
                           </content>].
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>Following single IV infusion of 30 mg edaravone (half the recommended dosage of edaravone injection) over 60 minutes, mean C
  <sub>max</sub> and AUC
  <sub>0-∞</sub> of unchanged edaravone were 1.15- and 1.20-fold greater in the subjects with mild renal impairment (eGFR 60-89 mL/min/1.73m
  <sup>2</sup>), and were 1.25- and 1.29-fold greater in the subjects with moderate renal impairment (eGFR 30-59 mL/min/1.73m
  <sup>2</sup>) when compared to subjects with normal renal function, respectively. These changes in exposures are not considered to be clinically significant and therefore no dosage adjustments are necessary in patients with mild to moderate renal impairment. The effects of severe renal impairment on the pharmacokinetics of edaravone have not been studied.
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>Following single IV infusion of 30 mg edaravone (half of the recommended dose of edaravone injection) over 60 minutes, mean C
  <sub>max</sub> and AUC
  <sub>0-∞</sub> of unchanged edaravone were 1.20- and 1.07-fold greater in the subjects with mild hepatic impairment (Child-Pugh score 5 or 6), were 1.24- and 1.14-fold greater in the subjects with moderate hepatic impairment (Child-Pugh score 7 to 9), and were 1.20- and 1.19-fold greater in the subjects with severe hepatic impairment (Child-Pugh score 10 to 14) when compared to subjects with normal hepatic function, respectively. These changes in exposures are not considered to be clinically significant and therefore no dosage adjustments are necessary in patients with hepatic impairment.
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Male and Female Patients</content>
                        </paragraph>
                        <paragraph>No gender effect on edaravone pharmacokinetics has been found.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Racial or Ethnic Groups</content>
                        </paragraph>
                        <paragraph>There were no significant racial differences in C
  <sub>max</sub> and AUC of edaravone between Japanese and Caucasian subjects.
 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of edaravone is not expected to be significantly affected by inhibitors of cytochrome P450 (CYP) enzymes, UGTs or major transporters.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> studies demonstrated that, at the recommended dosage, edaravone and its metabolites are not expected to significantly inhibit CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A), conjugating enzymes UGT1A1 and UGT2B7, or other transporters (P-gp, OATP1B1, OATP1B3, OAT1, OCT2, MATE1, and MATE2-K) in humans. Edaravone and its metabolites are not expected to induce CYP1A2, or CYP2B6, at the recommended dosage of edaravone.
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> data indicated that edaravone was not a substrate of OATP1B1 or OATP1B3.
 </paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_fff2075e-a871-4223-9e26-d79d5b17e77e">
               <id root="2553f0d7-c614-3c4a-e063-6394a90a3082"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13 NONCLINICAL TOXICOLOGY</content>
               </title>
               <text/>
               <effectiveTime value="20240930"/>
               <component>
                  <section ID="LINK_aeba62f5-c075-416f-9208-d533edb48fb3">
                     <id root="2553d778-ecff-e7bb-e063-6294a90a7592"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Carcinogenicity studies of edaravone using the intravenous route have not been conducted.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Edaravone was negative in 
  <content styleCode="italics">in vitro</content> (bacterial reverse mutation and Chinese hamster lung chromosomal aberration) and 
  <content styleCode="italics">in vivo</content> (mouse micronucleus) assays.
 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Intravenous administration of edaravone (0, 3, 20, or 200 mg/kg) prior to and throughout mating in male and female rats and continuing in females to gestation day 7 had no effect on fertility; however, disruption of the estrus cycle and mating behavior was observed at the highest dose tested. No effects on reproductive function were observed at the lower doses, which are up to approximately 3 times the RHD for edaravone injection (60 mg) on a body surface area (mg/m
  <sup>2</sup>) basis.
 </paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5636b5b7-b3cb-4097-901f-286147605c85">
               <id root="255416e2-9878-111b-e063-6394a90aa85e"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14 CLINICAL STUDIES</content>
               </title>
               <text>
                  <paragraph>The efficacy of edaravone injection for the treatment of ALS was established in a 6-month, randomized, placebo-controlled, double-blind study conducted in Japanese patients with ALS who were living independently and met the following criteria at screening:</paragraph>
                  <list listType="ordered">
                     <item>Functionality retained most activities of daily living (defined as scores of 2 points or better on each individual item of the ALS Functional Rating Scale - Revised [ALSFRS-R; described below])</item>
                     <item>Normal respiratory function (defined as percent-predicted forced vital capacity values of [%FVC] ≥80%)</item>
                     <item>Definite or Probable ALS based on El Escorial revised criteria</item>
                     <item>Disease duration of 2 years or less</item>
                  </list>
                  <paragraph>The study enrolled 69 patients in the edaravone injection arm and 68 in the placebo arm. Baseline characteristics were similar between these groups, with over 90% of patients in each group being treated with riluzole.</paragraph>
                  <paragraph>Edaravone injection was administered as an intravenous infusion of 60 mg given over a 60-minute period according to the following schedule:</paragraph>
                  <list listType="unordered">
                     <item>An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug-free period (Cycle 1)</item>
                     <item>Subsequent treatment cycles with daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods (Cycles 2-6).</item>
                  </list>
                  <paragraph>The primary efficacy endpoint was a comparison of the change between treatment arms in the ALSFRS-R total scores from baseline to Week 24. The ALSFRS-R scale consists of 12 questions that evaluate the fine motor, gross motor, bulbar, and respiratory function of patients with ALS (speech, salivation, swallowing, handwriting, cutting food, dressing/hygiene, turning in bed, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency). Each item is scored from 0-4, with higher scores representing greater functional ability. The decline in ALSFRS-R scores from baseline was significantly less in the edaravone injection-treated patients as compared to placebo (see Table 3). The distribution of change in ALSFRS-R scores from baseline to Week 24 by percent of patients is shown in Figure 1.</paragraph>
                  <table width="80%">
                     <caption>Table 3: Analysis of Change from Baseline to Week 24 in ALSFRS-R Scores</caption>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule">
                              <content styleCode="bold">Treatment</content>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule">
                              <paragraph>
                                 <content styleCode="bold">Change from Baseline</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">LS Mean ± SE(95% CI)</content>
                              </paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule">
                              <paragraph>
                                 <content styleCode="bold">Treatment Difference
       <br/>
			(
      </content>
                                 <content styleCode="bold">Edaravone Injection – placebo [95% CI])</content>
                              </paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule">
                              <content styleCode="bold">
                                 <content styleCode="italics">p</content>-value 
     </content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule">Edaravone Injection</td>
                           <td styleCode="Lrule Rrule Toprule Botrule">−5.01±0.64</td>
                           <td styleCode="Lrule Rrule Toprule Botrule">2.49 (0.99, 3.98)</td>
                           <td styleCode="Lrule Rrule Toprule Botrule">0.0013</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule">Placebo</td>
                           <td styleCode="Lrule Rrule Toprule Botrule">−7.50±0.66</td>
                           <td styleCode="Lrule Rrule Toprule Botrule"/>
                           <td styleCode="Lrule Rrule Toprule Botrule"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Figure 1 Distribution of Change from Baseline to Week 24 in ALSFRS-R Scores</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Le2fb5484-2d75-419a-83c5-fe4e5716a48e"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240930"/>
               <component>
                  <observationMedia ID="Le2fb5484-2d75-419a-83c5-fe4e5716a48e">
                     <text>figure-1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c923ac1d-e77a-4bd3-8cbf-13f2bea81db5">
               <id root="316d350d-b5d2-5612-e063-6294a90ae957"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16 HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250327"/>
               <component>
                  <section ID="L48fe580f-8cd4-4718-97ba-9aac1636c5c1">
                     <id root="316d250b-6f0f-4dba-e063-6294a90a5819"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>
                        <content styleCode="bold">16.1 How Supplied</content>
                     </title>
                     <text>
                        <paragraph>Edaravone injection is supplied as a 30 mg/100 mL (0.3 mg/mL) clear, colorless, sterile solution for intravenous infusion in single-dose USP Type 1 Glass Vial 
  <content styleCode="italics">[see </content>
                           <linkHtml href="#LINK_8f6f9eda-b9dd-448a-a787-e9318eccdc35">DOSAGE AND ADMINISTRATION (2.2)</linkHtml>
                           <content styleCode="italics">and 
   <linkHtml href="#L428e24f6-7878-4b8f-aff9-baed84e620eb">HOW SUPPLIED/STORAGE AND HANDLING (16.2)</linkHtml>]
  </content>. These are supplied in cartons as listed below.
 </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="italics">30 mg/100 mL: </content>
                              </content>NDC 39822-4500-1 single-dose glass vial, 2 vial per carton NDC 39822-4500-2
  </item>
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="italics">60 mg/100 mL:</content>
                              </content> NDC 39822-4510-1 single-dose glass vial, 1 vial per carton NDC 39822-4510-1
  </item>
                        </list>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
               <component>
                  <section ID="L428e24f6-7878-4b8f-aff9-baed84e620eb">
                     <id root="2554252d-2ac6-c211-e063-6394a90ae69d"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>
                        <content styleCode="bold">16.2 Storage and Handling</content>
                     </title>
                     <text>
                        <paragraph>Store edaravone injection at up to 25°C (77°F). Excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light.</paragraph>
                     </text>
                     <effectiveTime value="20240930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_1c7becee-f43f-423e-91fa-d91ef76bd278">
               <id root="2589811b-a813-ce48-e063-6394a90a28a2"/>
               <code code="88436-1" codeSystem="2.16.840.1.113883.6.1" displayName="PATIENT COUNSELING INFORMATION"/>
               <title>
                  <content styleCode="bold">17 PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph/>
                  <paragraph>Advise the patients to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients to seek immediate medical care if they experience signs or symptoms of a hypersensitivity reaction 
  <content styleCode="italics">[see 
   <linkHtml href="#LINK_61a646af-fb4f-47da-8a04-d800e6075f02">WARNINGS AND PRECAUTIONS (5.1)</linkHtml>]
  </content>.
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Sulfite Allergic Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients about potential for sulfite sensitivity. Inform patients that edaravone injection contains sodium bisulfite, which may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, and to seek immediate medical care if they experience these signs or symptoms 
  <content styleCode="italics">[see 
   <linkHtml href="#LINK_35f3097b-ee84-4bc0-8ac3-db6c06f198ca">WARNINGS AND PRECAUTIONS (5.2)</linkHtml>]
  </content>.
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy and Breastfeeding</content>
                  </paragraph>
                  <paragraph>Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during edaravone injection therapy 
  <content styleCode="italics">[see 
   <linkHtml href="#LINK_f3b5e246-a1b2-40bc-b38a-b6d17e6c1b81">USE IN SPECIFIC POPULATIONS (8.1)</linkHtml>]
  </content>.
 </paragraph>
                  <paragraph>Advise patients to notify their healthcare provider if they intend to breastfeed or are breastfeeding an infant 
  <content styleCode="italics">[see 
   <linkHtml href="#Lc836ab95-0e14-455d-b675-89c0733a066d">USE IN SPECIFIC POPULATIONS (8.2)</linkHtml>]
  </content>.
 </paragraph>
                  <paragraph>Manufactured in India</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Manufactured for:
  <br/>
XGen Pharmaceuticals DJB, Inc.
  <br/>
Big Flats, NY 14814
 </paragraph>
                  <paragraph>Revised: 09/2024
  <br/>
EDAR-PI-01
 </paragraph>
                  <paragraph>RADICAVA ORS® is a registered trademark of Mitsubishi Tanabe Pharma Corporation.</paragraph>
                  <paragraph>TN00006382</paragraph>
               </text>
               <effectiveTime value="20240930"/>
            </section>
         </component>
         <component>
            <section ID="id_link_258a7bdc-55c6-6018-e063-6394a90ae146">
               <id root="258ab6f2-f1a5-2d0d-e063-6294a90af34a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">PATIENT INFORMATION</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">EDARAVONE INJECTION</content>
                  </paragraph>
                  <paragraph>(e-dar-a-vone)</paragraph>
                  <paragraph>For Intravenous Infusion</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is edaravone injection?</content>
                     <br/>
Edaravone injection is a prescription medicine used to treat people with amyotrophic lateral sclerosis (ALS).
 </paragraph>
                  <paragraph>It is not known if edaravone injection is safe and effective in children.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not receive edaravone injection if you</content> are allergic to edaravone or any of the ingredients in edaravone injection. See the end of this leaflet for a complete list of ingredients in edaravone injection.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before you receive edaravone injection, tell your healthcare provider about all of your medical conditions, including if you:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>have asthma.</item>
                     <item>are allergic to other medicines.</item>
                     <item>are pregnant or plan to become pregnant. It is not known if edaravone injection will harm your unborn baby.</item>
                     <item>are breastfeeding or plan to breastfeed. It is not known if edaravone passes into your breastmilk. You and your healthcare provider should decide if you will receive edaravone injection or breastfeed.</item>
                  </list>
                  <paragraph>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How will I receive edaravone injection?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>You will be prescribed edaravone injection by a healthcare provider and told how often you will receive edaravone injection.</item>
                     <item>Edaravone injection will be given by intravenous (IV) infusion into your vein.</item>
                     <item>It takes about 1 hour to receive the full dose of edaravone injection.</item>
                     <item>Your healthcare provider will monitor you closely during your treatment with edaravone injection.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of edaravone injection?</content>
                     <br/>
Edaravone injection may cause serious side effects including:
 </paragraph>
                  <list listType="ordered">
                     <item>Hypersensitivity (allergic) reactions. Hypersensitivity reactions have happened in people receiving edaravone injection and can happen after your medicine has been given. Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms:</item>
                  </list>
                  <list listType="unordered">
                     <item>hives</item>
                     <item>swelling of the lips, tongue, face</item>
                     <item>breathing problems</item>
                     <item>dizziness</item>
                     <item>itching</item>
                     <item>wheezing</item>
                     <item>fainting</item>
                  </list>
                  <list listType="ordered">
                     <item>Sulfite allergic reactions. Edaravone injection contains sodium bisulfite, a sulfite that may cause a type of allergic reaction that can be serious and life-threatening. Sodium bisulfite can also cause less severe allergic reactions, for example, asthma episodes, in certain people. Sulfite sensitivity can happen more often in people who have asthma than in people who do not have asthma. Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms:</item>
                  </list>
                  <list listType="unordered">
                     <item>hives</item>
                     <item>swelling of the lips, tongue, face</item>
                     <item>trouble breathing or swallowing</item>
                     <item>dizziness</item>
                     <item>itching</item>
                     <item>asthma attack (in people with asthma)</item>
                     <item>wheezing</item>
                     <item>fainting</item>
                  </list>
                  <paragraph>Your healthcare provider will monitor you during treatment to watch for signs and symptoms of all serious side effects and allergic reactions.</paragraph>
                  <paragraph>The most common side effects of edaravone injection include bruising (contusion), problems walking (gait disturbance), and headache.</paragraph>
                  <paragraph>These are not all the possible side effects of edaravone injection. For more information, ask your healthcare provider or pharmacist.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to www.fda.gov/medwatch or XGen Pharmaceuticals DJB, Inc. at 1-866-390-4411.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in edaravone injection?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredient: </content>edaravone
  <br/>
                     <content styleCode="bold">Inactive ingredients:</content> L-cysteine hydrochloride hydrate, sodium bisulfite, sodium chloride (tonicity agent), phosphoric acid (pH adjuster), and sodium hydroxide (pH adjuster).
 </paragraph>
                  <paragraph>Manufactured in India for:
  <br/>
XGen Pharmaceuticals DJB, Inc., Big Flats, NY 14814
 </paragraph>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration</paragraph>
                  <paragraph>Issued: 09/2024
  <br/>
EDAR-PIL-01
 </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20240930"/>
            </section>
         </component>
         <component>
            <section ID="L3b76c52f-e01d-4f43-8df6-8e0cfd86e3fe">
               <id root="32826f0f-20e2-27e7-e063-6294a90a6742"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_22f36d7f-1bf1-a53b-e063-6394a90a5a3e"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_22f35fac-1afa-790a-e063-6394a90a9f1b"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_3282680c-c4b6-20a3-e063-6294a90ac582"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_3282680c-c4b7-20a3-e063-6294a90ac582"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250411"/>
               <component>
                  <observationMedia ID="img_22f36d7f-1bf1-a53b-e063-6394a90a5a3e">
                     <text>30 mg vial</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="30 mg vial photo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_22f35fac-1afa-790a-e063-6394a90a9f1b">
                     <text>60 mg vial</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="60 mg vial photo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_3282680c-c4b6-20a3-e063-6294a90ac582">
                     <text>30 mg carton photo.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="30 mg carton photo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_3282680c-c4b7-20a3-e063-6294a90ac582">
                     <text>60 mg carton photo.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="60 mg carton photo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>